A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice

A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice

In this work, we evaluated recombinant receptor binding domain (RBD)-based vaccine formulation prototypes with potential for further clinical development. We assessed different formulations containing RBD plus alum, AddaS03, AddaVax, or the combination of alum and U-Omp19: a novel Brucella spp. prot...

Full description

Bibliographic Details
Main Authors: Lorena M. Coria, Lucas M. Saposnik, Celeste Pueblas Castro, Eliana F. Castro, Laura A. Bruno, William B. Stone, Paula S. Pérez, Maria Laura Darriba, Lucia B. Chemes, Julieta Alcain, Ignacio Mazzitelli, Augusto Varese, Melina Salvatori, Albert J. Auguste, Diego E. Álvarez, Karina A. Pasquevich, Juliana Cassataro
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-02-01
Series:Frontiers in Immunology
Subjects:
adjuvant
protease inhibitor
SARS- CoV-2
U-Omp19
germinal center cells
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.844837/full

Similar Items

Similar Items